Oxagen Limited is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets. The lead programme is to develop a small molecule to target a GPCR, designated
OG466. The lead molecule, ODC9101 inhibits the activity of OG466, offering the potential to treat asthma and other respiratory and inflammatory related conditions.
Oxagen is based near Oxford, UK. The Company has in-house preclinical and development staff managing a series of contract research relationships with outside suppliers in pre-clinical testing, medicinal and formulation chemistry and conduct of clinical trials.
Recently re-funded through a $60M investment round led by MPM Capital (see press release), Oxagen is a private company, founded in 1997 and financed by a group of high quality venture capital firms.
| Contact Details: |
| 91 Milton Park |
| Abingdon |
| Oxfordshire |
| OX14 4RY |
| United Kingdom |
| Tel: | 44(0) 1235 443300 |
| Fax: | 44(0) 1235 443301 |
| Email: | oxagen@oxagen.co.uk |
| WWW: | www.oxagen.co.uk/
|
|
Loading...
|
Recent Publications by Oxagen Limited: |  |
Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway.
It is now well established that interaction of PGD(2) with chemoattractant... | 26th June, 2009
| Oxagen
| J Immunol. 2009 Jun 15;182(12):7580-6.
DOI Direct Link |
Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells.
The mechanisms by which immunologically activated mast cells stimulate the... | 17th June, 2009
|
| Clin Exp Immunol. 2009 Apr;156(1):126-33. Epub 2009 Feb 11.
DOI Direct Link |
Antagonists of the prostaglandin D2 receptor CRTH2.
Prostaglandin D(2) (PGD(2)) is produced by mast cells, Th2 lymphocytes and... | 16th January, 2009
| Pharmacology, Oxagen
| Drug News Perspect. 2008 Jul-Aug;21(6):317-22.
DOI Direct Link |
Use of commercially available radiation hybrid panels.
Several panels are available for puchase, and this unit provides update... | 24th May, 2008
| Oxagen, Ltd., Abingdon, United Kingdom.
| Curr Protoc Hum Genet. 2001 May;Chapter 3:Unit 3.5.
DOI Direct Link |
The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses.
Prostaglandin D(2) (PGD(2)) is produced by mast cells, Th2 lymphocytes and... | 29th April, 2008
| Oxagen Ltd, 91 Milton
| Br J Pharmacol. 2008 Mar;153 Suppl 1:S191-9. Epub 2007 Oct 29.
DOI Direct Link |
→View more Oxagen Limited research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 1124 times since April 2007, the link to the organisation's website has been followed 103 times
Recent Search Terms used to find this page: oxagen limited-1 | gpcr oxfordshire | oxagen ltd | oxagen clinical trials | oxagen | .
Search for more companies in Abingdon
Search for more companies in Oxfordshire
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Oxagen Limited
